Managers / Q3 2021 · view latest →
HARBOURVEST PARTNERS LLC
CIK 0001201001 · ONE LINCOLN STREET, SUITE 1700, BOSTON, MA, 02111 · 617-348-3707
Reported Value
$1.1B
Q3 2021
Positions
56
Filings on Record
32
2019–present window
Filed
Nov 15, 2021
original filing
Summary
Harbourvest Partners LLC reported $1.1B in U.S.-listed holdings across 56 positions for Q3 2021.
The portfolio is heavily concentrated: MNDY alone accounts for 36.1% of reported value.
Compared with Q2 2021, the fund opened 16 new positions and exited 11.
Portfolio Metrics
Turnover
+24.5%
vs prior filed quarter
Top-10 Concentration
+87.2%
share of reported value
Largest Position
+36.1%
Monday Com
New / Exited
16 / 11
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 88.6% · $943M
- Other · 11.3% · $120M
- ADR · 0.2% · $2M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| Omega Therapeutics, Inc. | NEW | +2.65M | 2.65M | +$50M | $50M |
| NABLN-Able, Inc. | NEW | +3.72M | 3.72M | +$46M | $46M |
| TEADOutbrain Inc. | NEW | +1.62M | 1.62M | +$24M | $24M |
| WRBYWarby Parker Inc. | NEW | +153.5K | 153.5K | +$8M | $8M |
| NETCloudflare, Inc. | NEW | +65.0K | 65.0K | +$7M | $7M |
| Olo, Inc. | NEW | +114.1K | 114.1K | +$3M | $3M |
| OKTAOkta Inc. | NEW | +12.7K | 12.7K | +$3M | $3M |
| PINSPinterest, Inc. | NEW | +54.6K | 54.6K | +$3M | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2021
56 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MNDYMonday.comhistory → | SHS | 36.11% | $384M | 1.18M |
| 2 | WWayfair, Inc.history → | Common CLA | 25.49% | $271M | 1.06M |
| 3 | Solarwinds Corp. | Common | 5.85% | $62M | 3.72M |
| 4 | Omega Therapeutics, Inc. | Common | 4.69% | $50M | 2.65M |
| 5 | NABLN-Able, Inc.history → | Common | 4.34% | $46M | 3.72M |
| 6 | Bright Health Group, Inc. | Common | 3.23% | $34M | 4.22M |
| 7 | TEADOutbrain Inc.history → | Common | 2.25% | $24M | 1.62M |
| 8 | Evelo Biosciences, Inc. | Common | 2.03% | $22M | 3.06M |
| 9 | Rubius Therapeutics, Inc. | Common | 1.66% | $18M | 986.9K |
| 10 | FTCHQFarfetch Ltd.history → | Ordinary Shares CLA | 1.56% | $17M | 442.7K |
| 11 | WHDCactus, Inc.history → | Common CLA | 1.39% | $15M | 392.9K |
| 12 | LendingClub Corp. | Common | 1.36% | $15M | 513.4K |
| 13 | KLDOKaleido BioSciences, Inc.history → | Common | 0.94% | $10M | 1.83M |
| 14 | RLAYRelay Therapeutics, Inc. | Common | 0.88% | $9M | 296.4K |
| 15 | Axcella Health, Inc. | Common | 0.79% | $8M | 2.81M |
| 16 | WRBYWarby Parker Inc. | Common CLA | 0.77% | $8M | 153.5K |
| 17 | PATHUiPath, Inc. | Common CLA | 0.71% | $8M | 144.2K |
| 18 | NETCloudflare, Inc. | Common CLA | 0.69% | $7M | 65.0K |
| 19 | TWLOTwilio, Inc. | Common CLA | 0.44% | $5M | 14.6K |
| 20 | Sigilon Therapeutics, Inc. | Common | 0.39% | $4M | 740.7K |
| 21 | CVRXCVRx, Inc. | Common | 0.33% | $4M | 213.5K |
| 22 | Olo, Inc. | Common CLA | 0.32% | $3M | 114.1K |
| 23 | IBRXImmunityBio, Inc. | Common | 0.31% | $3M | 335.7K |
| 24 | Inari Medical | Common | 0.29% | $3M | 38.5K |
| 25 | OKTAOkta Inc. | Common CLA | 0.28% | $3M | 12.7K |
| 26 | PINSPinterest, Inc. | Common CLA | 0.26% | $3M | 54.6K |
| 27 | CRWDCrowdStrike Holdings, Inc | Common CLA | 0.26% | $3M | 11.1K |
| 28 | Zuora, Inc. | Common | 0.26% | $3M | 163.9K |
| 29 | ONTFON24, Inc. | Common | 0.20% | $2M | 109.2K |
| 30 | Eventbrite, Inc. | Common CLA | 0.19% | $2M | 106.1K |
| 31 | Spark Networks SE | Sponsored ADR | 0.17% | $2M | 501.0K |
| 32 | ARVNArvinas, Inc. | Common | 0.16% | $2M | 21.1K |
| 33 | COURCoursera, Inc. | Common | 0.16% | $2M | 53.1K |
| 34 | Sumo Logic, Inc. | Common | 0.14% | $2M | 93.0K |
| 35 | PUBMPubMatic, Inc. | Common CLA | 0.13% | $1M | 54.5K |
| 36 | YEXTYext, Inc. | Common | 0.13% | $1M | 115.1K |
| 37 | NRIXNurix Therapeutics, Inc. | Common | 0.11% | $1M | 39.8K |
| 38 | Root, Inc. | Common CLA | 0.10% | $1M | 204.3K |
| 39 | ACVAACV Auctions, Inc. | Common CLA | 0.08% | $837,000 | 46.8K |
| 40 | Duck Creek Technologies, Inc. | SHS | 0.06% | $642,000 | 14.5K |
| 41 | UUnity Software | Common | 0.06% | $623,000 | 4.9K |
| 42 | PACBPacific Biosciences of California, Inc. | Common | 0.06% | $600,000 | 23.5K |
| 43 | Castlight Health, Inc. | Common CLB | 0.05% | $548,000 | 349.1K |
| 44 | SNDXSyndax Pharmaceuticals, Inc. | Common | 0.05% | $545,000 | 28.5K |
| 45 | DELLDell, Inc. | Common CLC | 0.05% | $525,000 | 5.0K |
| 46 | CTMXCytomx Therapeutics, Inc. | Common | 0.04% | $403,000 | 79.2K |
| 47 | Seres Therapeutics, Inc. | Common | 0.03% | $344,000 | 49.4K |
| 48 | RPTXRepare Therapeutics, Inc. | Common | 0.03% | $322,000 | 12.3K |
| 49 | Aligos Therapeutics, Inc. | Common | 0.03% | $291,000 | 18.8K |
| 50 | Trevena, Inc. | Common | 0.03% | $288,000 | 233.8K |
| 51 | PMVPPMV Pharmaceuticals | Common | 0.02% | $229,000 | 7.7K |
| 52 | Yumanity | Common | 0.02% | $227,000 | 22.0K |
| 53 | OYSTOyster Point Pharma, Inc. | Common | 0.01% | $149,000 | 12.6K |
| 54 | LTCHLatch, Inc. | Common | 0.01% | $126,000 | 11.2K |
| 55 | Epizyme, Inc. | Common | 0.01% | $126,000 | 24.7K |
| 56 | NextCure, Inc. | Common | 0.01% | $68,000 | 10.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $101M | 5 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $174M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $205M | 9 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $91M | 15 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $154M | 16 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $203M | 22 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $192M | 34 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $188M | 40 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $219M | 48 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $299M | 53 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $295M | 58 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $352M | 60 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $297M | 63 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $299M | 65 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $306M | 67 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $305M | 62 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $490M | 66 | May 26, 2022 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2021 | $782M | 67 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.1B | 56 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.0B | 51 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $746M | 44 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $256M | 26 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $270M | 36 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $232M | 28 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $207M | 36 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $243M | 35 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $240M | 33 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $262M | 32 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $283M | 33 | May 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $211M | 32 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.